As the world’s second-largest healthcare market, China spends about $575 billion a year on the sector, roughly equivalent to Sweden’s GDP. But because of China’s large population, that translates into only $420 in per capita healthcare spending, just 4% of what an average American spends. This healthcare supply shortage is exacerbated by rising demand from wealthier Chinese who seek quality care, better insurance, and diverse services.
On the regulatory side, the Chinese government continues to reform the healthcare sector by allowing doctors to work
outside the public hospital system, encouraging the privatization of hospitals, and expanding public healthcare insurance to cover private hospitals.
The significant mismatch between supply and demand, coupled with policy changes to support the sector, have incentivized private investment to flock into areas ranging from advanced pharmaceuticals and medical devices to primary care clinics, elderly care, and insurance products.
Anhui Fengyuan Pharmaceutical focuses on the manufacture and distribution of biomedicine, chemical synthetic medicines, as well as traditional Chinese medicine. The company has more than 30 distribution and service centers across China.
He Hongman
Hefei, Anhui
(551) 6484.6018
xlyyzj@163.com
France Belgium Argentina Brazil Hungary
BBFY Industrial USA Inc. 07 18511 E. Gale Ave. Industry, CA 91748 626.965.2800
In 2015, the company co-invested with Hungarian Development Bank and Szolnok Industrial Park in a citric acid manufacturing facility in Hungary. The total investment amount was estimated to be $155 million and is expected to create more than 200 jobs.